Refreshing the biologic pipeline 2020.

Hodgson, John · Nat Biotechnol · 2021

editorial · Level V

Where this comes from

Abstract

In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay.

Medical subject headings